Recent Company News

• 02:46 AM ET Jun 13, 2025
  

  Japan Tobacco shows positive top-line results of JTE-051 phase 2 study for treatment for interstitial cystitis/bladder pain syndrome (¥4336.0000, 0)

• 02:34 AM ET May 14, 2025
  

  Japan Tobacco and Torii Pharmaceutical report preliminary results of bioequivalence study of JAK inhibitor "JTE-052 (Delgocitinib)" (¥4370.0000, 0)

• 07:04 PM ET May 08, 2025
  

  Japan Tobacco initiated B+ at Iwai Cosmo Securities (¥4559.0000, 0)

• 02:53 AM ET May 07, 2025
  

  Shionogi & Co confirms launch of tender offer to acquire 45.2% stake in Torii Pharmaceutical for ¥6,350/share or ¥80.72B (¥5580.0000, 0)

• 02:39 AM ET May 07, 2025
  

  Japan Tobacco reports Q1 net income attributable ¥157.48B vs FactSet ¥144.50B [1 est] (¥4502.0000, 0)

• 01:48 AM ET May 07, 2025
  

  Shionogi & Co to acquire Torii Pharmaceutical for ¥150B - Nikkei (¥5580.0000, +350)

• 06:12 PM ET Mar 24, 2025
  

  Japan Tobacco upgraded to buy from neutral at Goldman Sachs (¥4060.0000, 0)

• 02:42 AM ET Mar 10, 2025
  

  Japan Tobacco to record ¥375.6B provision for litigation losses in FY24 earnings; reaffirms FY25 guidance (¥3865.0000, 0)

• 08:42 AM ET Mar 07, 2025
  

  ALK-Abello announces ACARIZAX approved in Canada for treatment of young children; regulatory reviews of ITULAZAX in EU and Canada expected to complete middle 2025 (DKK 144.30, +1.80)

• 07:43 PM ET Mar 02, 2025
  

  Japan Tobacco reaches settlement in Canada, to set aside under ¥400B as provision (pre-Japan open) (¥3773.0000, +23)